Dr. Reddy's Laboratories Limited NSE Symbol: DRREDDY BSE Script Code: 500124 a global pharmaceutical company collaborates with the Russian Direct Investment Fund (RDIF) for conduction of clinical trials and distribution of the Sputnik V vaccine in India. Upon approval, Dr Reddy’s is to be supplied with 100 million doses of the vaccine from the RDIF. According to Dr. Reddy’s Lab The Sputnik V based on the human adenoviral vector platform, has proven safety and is undergoing clinical trials for the coronavirus pandemic. Upon completion of successful trials and registration the distribution of the vaccine could start as early as the end of 2020. The cooperation between Dr Reddy’s and the RDIF reflects a growing awareness among countries and organizations and their attempts to create a diversified anti-COVID vaccine portfolio.
The Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and as of August 11 became the world’s first registered vaccine against COVID-19.
On September 4, 2020, The Lancet published a research paper on the results of the Phase I and Phase II clinical trials of the vaccine. According to the paper, it demonstrated no serious side-effects and had a stable immune response in all participants. Post-registration clinical trials of the Sputnik V vaccine involving 40,000 volunteers are currently in progress and the first results of these trials are expected to be published in October-November 2020.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said, “We are very pleased to partner with Dr. Reddy’s in India.” He then goes on to say, “India is among the most severely impacted countries from COVID 19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against COVID 19. RDIF partners will receive an effective and safe drug to fight the coronavirus”
G V Prasad, Co-Chairman & Managing Director of Dr. Reddy’s Laboratories said, “The Phase I and II clinical trials have shown promising results. We will be conducting Phase-III trials in India to ensure safety and efficacy for the Indian population and to meet the requirements of the Indian regulators.”